Omega-3 vs Coenzyme Q10: what to choose and for whom

“What is better to take for the heart and endurance — omega-3 or Q10?” is one of the most frequent questions our editorial team receives. The right answer depends not on which supplement is “stronger”, but on which problem you want to solve. In this article we break down specific scenarios and explain how to make a choice without overpaying.

Start with the goal, not the supplement

Omega-3 and coenzyme Q10 solve different tasks, so comparing them “head to head” is incorrect. Before buying either of them, it is worth answering honestly: what exactly do I want to change, and how will I measure it? Without such an answer a supplement turns into a ritual rather than a tool.

The most common motives with which people come to these supplements are “for the heart”, “for energy”, “for recovery after workouts” and “because the doctor prescribed statins”. For each of them the answer will be different, and that is exactly what determines the choice.

The second filter is your diet. Someone who eats oily fish twice a week already gets a noticeable amount of EPA and DHA, whereas for those who barely eat fish, omega-3 fills a real deficit. With Q10 the situation is different: its stores depend more on age, health status and medications than on the menu.

The third filter is existing conditions and therapy. Anticoagulants, cardiac rhythm disorders, heart failure or statin use change both the benefit-to-risk ratio and the choice itself. In these cases the decision should be made together with a doctor.

Who should choose omega-3

The first and largest group is people who rarely eat oily marine fish. For them omega-3 is a way to bring EPA and DHA intake closer to recommended levels. EFSA considers about 250 mg of EPA+DHA per day sufficient for adults, which roughly corresponds to one or two servings of oily fish per week.

The second group is people with elevated triglycerides. Here the effect of omega-3 is most predictable and dose-dependent, but therapeutic doses (several grams per day) and prescription drugs are prescribed by a doctor, who also monitors the lipid panel over time.

The third group is athletes with a large training volume. Reviews suggest that omega-3s may somewhat reduce the sensation of delayed-onset muscle soreness and support recovery, and in the study by Smith and colleagues (2015) fish oil intake in older people was accompanied by an increase in muscle mass and function. This is not an “anabolic”, but a useful addition to proper nutrition.

The fourth group is vegetarians and vegans. For them omega-3s from microalgae, which contain DHA (and often EPA) without a fish origin, are relevant. Plant-based ALA from flax or chia does not by itself provide sufficient levels of the long-chain forms.

• little fish in the diet — basic omega-3 intake;
• high triglycerides — only under a doctor's supervision;
• intense training — as part of a recovery strategy;
• plant-based diet — microalgae oil.

Who might need coenzyme Q10

Coenzyme Q10 is a choice for a narrower audience. Its use looks most justified in patients with chronic heart failure as an addition to standard therapy: the Q-SYMBIO trial used 300 mg per day. But such a decision is made by a cardiologist, not by a customer in a shop.

The second group is people who take statins and complain of muscle pain. Statins lower blood Q10 levels, so the idea of “restoring” it looks logical. However, meta-analyses give contradictory results, so Q10 here is a “you can try it, in agreement with your doctor” option rather than a guaranteed solution. You should not stop statins on your own because of myalgia.

The third group is older people. The body's own synthesis of the coenzyme declines with the years, and some specialists view the supplement as support for energy metabolism. Still, convincing evidence of improved well-being or physical performance in healthy older people is so far scarce.

For young, healthy athletes coenzyme Q10 is most likely not to produce a noticeable gain in endurance: their own synthesis is sufficient, and studies of an ergogenic effect have mixed results. In such a case the money is better invested in quality protein, creatine or a consultation with a dietitian.

How to choose a quality product and how much to take

Choose omega-3 by its EPA and DHA content, not by the total weight of fish oil in the capsule. Behind “1000 mg of fish oil” on the label there may be only 300 mg of active acids. For preventive purposes one usually aims at 250–500 mg of EPA+DHA per day; higher doses are a matter for discussion with a doctor.

For coenzyme Q10, studies most often used 100–300 mg per day. Ubiquinone is the most studied and affordable form; ubiquinol costs more and may be better absorbed in some people, but a benefit for final clinical outcomes has not been proven.

Both supplements are fat-soluble, so they are best taken with meals. A strong rancid smell of fish oil is a sign of oxidation, and such a product is better not used.

While taking anticoagulants or warfarin, start either of these supplements only after a consultation: high-dose omega-3 theoretically increases bleeding, and Q10 can weaken the effect of warfarin.

When to combine them, and when it is unnecessary

Since omega-3 and Q10 act through different mechanisms, they do not interfere with each other and can be taken together. The only question is whether there is a reason for it. For a person with no diseases and a normal diet, taking both rarely gives anything beyond extra expense.

The combination may make sense in an older patient on statins who eats little fish: omega-3 closes the dietary deficit, while Q10 is considered an attempt to ease muscle symptoms. But even here the doctor should know about both supplements.

The opposite also happens: a person takes both supplements, although their “fatigue” is actually due to iron or vitamin D deficiency, lack of sleep or overtraining. In that case neither capsule will help until the real cause is addressed.

The editorial team's practical rule: one new supplement at a time, a clear goal and an evaluation deadline (for example, 8–12 weeks with a follow-up lipid panel for omega-3). That way you will understand what exactly is working.

Editorial conclusions

For most people who eat little fish, the priority supplement will be omega-3 — it closes a common dietary deficit and has a proven effect on triglycerides.

Coenzyme Q10 is a choice for specific cases: heart failure, statin use, older age — and always after talking to a doctor. Young, healthy athletes rarely need it.

You can combine both supplements, but only when there is a separate reason for each.

To understand the topic more deeply, we recommend our articles “Omega-3 or Coenzyme Q10: what's the difference”, a review of microalgae omega-3 for vegans and an article on how to read a lipid panel.

References

1. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA J. 2010;8(3):1461.
2. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
3. Smith GI, Julliand S, Reeds DN, et al. Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults. Am J Clin Nutr. 2015;102(1):115–122.
4. Philpott JD, Witard OC, Galloway SDR. Applications of omega-3 polyunsaturated fatty acid supplementation for sport performance. Res Sports Med. 2019;27(2):219–237.
5. Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641–649.
6. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24–34.
7. Manson JE, Cook NR, Lee IM, et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23–32.